Outcomes | Anticipated absolute effects (95% CI) | Relative effect (OR (95% CI)) | No. of participants (no. of studies) | Certainty of evidence (GRADE) | |
---|---|---|---|---|---|
Control | Risk difference with corticosteroids | ||||
All-cause 28- or 30-day mortality | 389 per 1000 | 109 fewer per 1000 (170 fewer to 38 fewer) | 0.61 (044–0.85) | 742 (4 RCTs) | Moderatea |
All-cause 60-day mortality | 381 per 1000 | 121 fewer per 1000 (183 fewer to 43 fewer) | 0.57 (040–0.83) | 565 (3 RCTs) | Moderatea |
Ventilator-free days at 28 days | MD 3.74 more (1.53 more to 5.95 more) | 742 (4 RCTs) | Lowa,b | ||
PaO2/FiO2 at days 6 or 7 | MD 54.22 more (33.5 more to 74.93 more) | 494 (3 RCTs) | Very lowa,c | ||
Hyperglycemia | 687 per 1000 | 82 more per 1000 (8 more to 142 more) | 1.52 (1.04–2.21) | 565 (3 RCTs) | Moderatea |
Nosocomial infections | 232 per 1000 | 28 fewer per 1000 (81 fewer to 36 more) | 0.85 (0.59–1.21) | 742 (4 RCTs) | Lowa,d |
Gastrointestinal bleeding | 31 per 1000 | 12 more per 1000 (19 fewer to 110 more) | 1.39 (0.38–5.06) | 374 (2 RCTs) | Lowa,d |